[{"id":"a1eea5cb-b85b-4c1a-ad3a-f7312c93e2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01350180","created_at":"2021-01-18T05:30:58.023Z","updated_at":"2025-02-25T15:05:02.987Z","phase":"","brief_title":"Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis","source_id_and_acronym":"NCT01350180","lead_sponsor":"Dr. Tamim Niazi","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2024-12-10"},{"id":"e1da699e-8459-4c05-8219-ccd0bd195e76","acronym":"","url":"https://clinicaltrials.gov/study/NCT01441687","created_at":"2021-01-18T05:58:33.072Z","updated_at":"2024-07-02T16:35:14.156Z","phase":"","brief_title":"Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome","source_id_and_acronym":"NCT01441687","lead_sponsor":"City of Hope Medical Center","biomarkers":" ERG • TMPRSS2","pipe":" | ","alterations":" TMPRSS2-ERG fusion","tags":["ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMPRSS2-ERG fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 243","initiation":"Initiation: 07/14/2009","start_date":" 07/14/2009","primary_txt":" Primary completion: 06/30/2016","primary_completion_date":" 06/30/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"7143627d-c8e8-461b-94ec-fbc84af3d151","acronym":"URODETECT-WP1","url":"https://clinicaltrials.gov/study/NCT05453604","created_at":"2022-07-12T10:54:37.868Z","updated_at":"2024-07-02T16:35:29.461Z","phase":"","brief_title":"Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications","source_id_and_acronym":"NCT05453604 - URODETECT-WP1","lead_sponsor":"Novosanis NV","biomarkers":" HER-2 • PIK3CA • AR • ERG • TMPRSS2","pipe":" | ","alterations":" AR splice variant 7","tags":["HER-2 • PIK3CA • AR • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-11-13"},{"id":"c6e6c882-acce-439b-98fd-2069d69504e3","acronym":"URODETECT-WP2","url":"https://clinicaltrials.gov/study/NCT05454371","created_at":"2022-07-12T10:54:47.254Z","updated_at":"2024-07-02T16:35:29.484Z","phase":"","brief_title":"Investigation of Urinary Biomarkers for the Detection of Prostate Cancer","source_id_and_acronym":"NCT05454371 - URODETECT-WP2","lead_sponsor":"Novosanis NV","biomarkers":" AR • ERG • TMPRSS2","pipe":" | ","alterations":" AR splice variant 7","tags":["AR • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-11-13"},{"id":"914653e2-dfa1-47cf-b128-9f2a0b04b4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075308","created_at":"2021-01-18T04:14:13.456Z","updated_at":"2024-07-02T16:35:41.030Z","phase":"Phase 2","brief_title":"SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer","source_id_and_acronym":"NCT01075308","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pracinostat (SB939)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 06/28/2010","start_date":" 06/28/2010","primary_txt":" Primary completion: 01/05/2015","primary_completion_date":" 01/05/2015","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"2b50d005-f052-4b55-a69c-67be5aa27c38","acronym":"","url":"https://clinicaltrials.gov/study/NCT02430480","created_at":"2021-01-18T11:37:46.360Z","updated_at":"2024-07-02T16:35:42.119Z","phase":"Phase 2","brief_title":"Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer","source_id_and_acronym":"NCT02430480","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • AR • ERG","pipe":" | ","alterations":" ERG overexpression","tags":["PTEN • AR • ERG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERG overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-25"},{"id":"ab87f7b8-10f9-4d94-840a-2a5b2223d4c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573636","created_at":"2021-01-18T12:28:21.038Z","updated_at":"2024-07-02T16:36:39.864Z","phase":"","brief_title":"The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy","source_id_and_acronym":"NCT02573636","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 208","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2020-10-20"},{"id":"64dc377c-8fcd-432d-95e8-37fc6bb1ae8c","acronym":"PROSABI","url":"https://clinicaltrials.gov/study/NCT02787837","created_at":"2021-01-18T13:40:35.180Z","updated_at":"2024-07-02T16:36:50.956Z","phase":"","brief_title":"PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.","source_id_and_acronym":"NCT02787837 - PROSABI","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"d865a9f7-2178-4ced-881c-a75158e29a4f","acronym":"PROSENZA","url":"https://clinicaltrials.gov/study/NCT02922218","created_at":"2021-01-18T14:20:52.861Z","updated_at":"2024-07-02T16:36:50.930Z","phase":"","brief_title":"PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.","source_id_and_acronym":"NCT02922218 - PROSENZA","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • AR • ERG","pipe":" | ","alterations":" AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["PTEN • AR • ERG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Unknown status","enrollment":" Enrollment 187","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"e4b470a6-e3f3-473a-b3dd-c583115f597e","acronym":"PROSTAC","url":"https://clinicaltrials.gov/study/NCT02362620","created_at":"2021-01-18T11:14:49.607Z","updated_at":"2024-07-02T16:36:50.915Z","phase":"","brief_title":"PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.","source_id_and_acronym":"NCT02362620 - PROSTAC","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 402","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"aba3eac3-509d-4c6f-88e7-e50f6a1bca58","acronym":"","url":"https://clinicaltrials.gov/study/NCT00910884","created_at":"2021-07-17T11:52:39.207Z","updated_at":"2024-07-02T16:36:51.225Z","phase":"","brief_title":"Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.","source_id_and_acronym":"NCT00910884","lead_sponsor":"Brabant Research","biomarkers":" ERG • TMPRSS2","pipe":" | ","alterations":" TMPRSS2-ERG fusion","tags":["ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMPRSS2-ERG fusion"],"overall_status":"Unknown status","enrollment":" Enrollment 300","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2020-01-18"},{"id":"6b8bf719-5c1e-4c86-a97f-384cf98014e4","acronym":"CHRU-WCMC","url":"https://clinicaltrials.gov/study/NCT03421015","created_at":"2021-01-18T16:52:39.017Z","updated_at":"2024-07-02T16:36:53.886Z","phase":"","brief_title":"Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution","source_id_and_acronym":"NCT03421015 - CHRU-WCMC","lead_sponsor":"University Hospital, Lille","biomarkers":" TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1","pipe":" | ","alterations":" TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion","tags":["TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion"],"overall_status":"Unknown status","enrollment":" Enrollment 84","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2019-11-07"},{"id":"0bc8b313-5200-4c6e-90af-8e807a306558","acronym":"Triptocare","url":"https://clinicaltrials.gov/study/NCT01020448","created_at":"2021-01-18T04:00:08.624Z","updated_at":"2024-07-02T16:37:03.377Z","phase":"Phase 3","brief_title":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","source_id_and_acronym":"NCT01020448 - Triptocare","lead_sponsor":"Ipsen","biomarkers":" ERG • TMPRSS2 • PCA3","pipe":"","alterations":" ","tags":["ERG • TMPRSS2 • PCA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Completed","enrollment":" Enrollment 339","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 11/01/2011","primary_completion_date":" 11/01/2011","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2019-01-30"},{"id":"eb853216-6770-42ac-b694-08e5c7477e36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588404","created_at":"2021-01-18T12:33:33.544Z","updated_at":"2024-07-02T16:37:30.172Z","phase":"","brief_title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","source_id_and_acronym":"NCT02588404","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" ERG • TMPRSS2","pipe":" | ","alterations":" TMPRSS2-ERG fusion","tags":["ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMPRSS2-ERG fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-28"}]